K. I. Salimzyanov

K. I. Salimzyanov

Auto-generated profile, based on publicly available information

K. I. Salimzyanov

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
SAS.A. Aksenov
S.A. Aksenov
VKV.M. Khomyakov
V.M. Khomyakov
ARA.B. Ryabov
A.B. Ryabov
IKI.V. Kolobaev
I.V. Kolobaev
DSD.D. Sobolev
D.D. Sobolev
AKAndrei Kaprin
Andrei Kaprin
Cytoreductive surgery in combination with preoperative chemotherapy (also known as conversion surgery) is a promising treatment option for patients with limited peritoneal carcinomatosis. Local chemotherapy combined with cytoreductive procedures is widely discussed in literature as preventive approach for intraoperative dissemination. Objective. To This study aimed to evaluate the safety and efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in combination with cytoreductive surgery for patients with gastric cancer and limited peritoneal carcinomatosis (PCI < 7). Material and methods. Between 2019 and 2023, in total 20 patients with gastric cancer and limited peritoneal carcinomatosis underwent cytoreductive surgeries combined with PIPAC session at the NMIC of Radiology, Ministry of Health, Russian Federation. Results. Of the 21 patients, 3 (31.1%) had a partial response, in 17 patients primary tumor stabilization was observed after preoperative treatment, in 10 patients (50%), a complete response of peritoneal metastasis was achieved. All patients underwent complete cytoreduction (R0/CC-0). Major pathological response of the primary tumor was achived in 2 (10%) patients — TRG1a per Becker and in 4 (20%) — TRG1b per Becker, TRG2 and TRG3 in 5 (25%) and 9 (45%) patients, respectively. The median overall survival was 27 months and the disease-free survival was 7 months. 1-year and 2-year overall survival rates were 95% and 60%, respectively. Conclusion. Cytoreductive surgery in combination with PIPAC is feasible and safe. The survival rates demonstrate the potential effectiveness of this method. However, in order to make a clear assessment of the efficacy of adjuvant intraperitoneal chemotherapy as an approach for preventing intraoperative dissemination during cytoreductions, further randomized controlled trials is needed.

20 February 2026 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
KSK.I. Salimzyanov
K.I. Salimzyanov
ARA.B. Ryabov
A.B. Ryabov
ESE.I. Smolenov
E.I. Smolenov
VKV.M. Khomyakov
V.M. Khomyakov
IKI.V. Kolobaev
I.V. Kolobaev
SAS.A. Aksenov
S.A. Aksenov
Today, maximum effectiveness in treating patients with esophageal cancer is achieved by reducing surgical complications and mortality. Proper selection of patients for surgical treatment is the most promising way to reduce complications and mortality. A clear understanding of the relationship between various risk factors and postoperative complications in the future will allow for a more careful approach to patient selection, counseling, and ultimately, high-quality preparation for surgery. Over the past few decades, many scales have been proposed in general surgery and oncosurgery to predict mortality. Significant progress has been made in developing models through the improvement of mathematical algorithms, automation of information systems, and the use of artificial intelligence systems, but the ideal tool does not yet exist. In the presented literature review, a search was conducted for the most valid preoperative scales for predicting the risks of postoperative mortality in patients after esophagectomy.

30 March 2023 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
KSK.I. Salimzyanov
K.I. Salimzyanov
ARA.B. Ryabov
A.B. Ryabov
VKV.M. Khomyakov
V.M. Khomyakov
SPS.S. Pirogov
S.S. Pirogov
DSD.D. Sobolev
D.D. Sobolev
To treat pyloric tumor stenosis is a difficult task, since when choosing a technique, it is necessary to evaluate several factors: the functional status of a patient, the prevalence of the tumor process, cancer prognosis, and the possibility of performing a radical operation. This comprehensive review presents the world literature data including an assessment of surgical and non-surgical treatment options and all aspects of the choice of tactics for pyloric tumor stenosis. As experience is accumulated, the development of modern technologies related to the treatment of tumor stenosis, there are changes in the understanding of the problem. Well-designed prospective studies will be able to more accurately identify the best treatment option for these patients.

5 November 2026 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
ARA. B. Ryabov
A. B. Ryabov
ASA. A. Smirnov
A. A. Smirnov
DSD. D. Sobolev
D. D. Sobolev
VKV. M. Khomyakov
V. M. Khomyakov
IKI. V. Kolobaev
I. V. Kolobaev
ГГГ. А. Гехт
Г. А. Гехт
We demonstrate a clinical case of successful total esophageal demucoization in a 69-year-old patient in order to eliminate salivary esophageal fistula and pleural empyema after laparoscopic proximal subtotal gastric resection for early gastric cancer complicated by the failure of esophageal anastomosis, followed by delayed coloesophagoplasty.

23 April 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
KSK.I. Salimzyanov
K.I. Salimzyanov
ARA.B. Ryabov
A.B. Ryabov
VKV.M. Khomyakov
V.M. Khomyakov
LBLarisa Bolotina
Larisa Bolotina
DSD.D. Sobolev
D.D. Sobolev
AKAndrei Kaprin
Andrei Kaprin
To date, the prognosis of patients with resectable forms of esophageal cancer remains unsatisfactory; therefore, over the past 5 years, interest in the use of immunotherapy as a component of combined treatment has increased. Immune checkpoint inhibitors have been used in unresectable and metastatic esophageal cancer for several years. In recent years, neoadjuvant immunotherapy has achieved impressive rates of tumor pathomorphological response to treatment in patients with early-stage non-small cell lung cancer, melanoma, bladder and colorectal cancers. In this review, we consider the results and rationale of clinical trials that may further lead to the introduction into clinical practice of immune checkpoint inhibitors as a component of combination treatment for resectable esophageal cancer. Data from ongoing trials evaluating long-term outcomes are awaited to answer the question regarding the efficacy of immunotherapy and to determine the most appropriate therapy regimen.

17 May 2026 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
KSK. I. Salimzyanov
K. I. Salimzyanov
ARA. B. Ryabov
A. B. Ryabov
VKV. M. Khomyakov
V. M. Khomyakov
IKI. V. Kolobaev
I. V. Kolobaev
ESE. I. Smolenov
E. I. Smolenov
BSB. I. Salimzyanov
B. I. Salimzyanov
Objective : to develop a preoperative model for predicting 90-day mortality to optimize treatment strategy in patients with resectable esophageal cancer and Siewert type I gastroesophageal junction cancer. Material and Methods . A retrospective cohort study included 225 patients with resectable esophageal cancer (n=179) and Siewert type I gastroesophageal junction cancer (n=46). A total of 79 preoperative variables were analyzed. Risk factors were selected using univariate and multivariate logistic regression. The dataset was randomly split into training and validation cohorts (70/30). The predictive model was developed using l1-regularized multivariable logistic regression and the TabNet neural network featuring a sparse attentive architecture that enables estimation of feature importance. Discriminative ability and calibration were assessed using AUCROC analysis and the Hosmer–Lemeshow test. Results. The in-hospital mortality, 30-day mortality and 90-day mortality rates were 8.9 % (n=20), 1.3 % (n=3), and 6.2 % (n=14), respectively. The most significant predictors of mortality included preoperative weight loss >10 %, grade 3–4 dysphagia, ECOG performance status ≥2, COPD, preoperative dyspnea, history of major thoracic surgery, TNM stage N2, tumor proximity to or invasion of the trachea/main bronchi, cerebrovascular disease history, diabetes mellitus, and complications during or after radiotherapy. The logistic regression model demonstrated an AUC-ROC of 0.86 (95 % Ci 0.79–0.92) in the training cohort and 0.77 (95 % CI 0.72–0.83) in the validation cohort. Calibration was supported by non-significant Hosmer–Lemeshow χ 2 tests in both cohorts: χ 2 =1.98, df=8 (p=0.98) and χ 2 =4.72, df=8 (p=0.78), respectively. The TabNet neural network achieved improved discrimination with AUC-ROC values of 0.95 (95 % CI 0.92–0.98) in the training cohort and 0.86 (95 % Ci 0.82–0.96) in the validation cohort; calibration results were χ 2 =8.38, df=8 (p=0.39) and χ 2 =9.46, df=8 (p=0.30), respectively. The model has been implemented as a software application and can be used in real-world clinical scenarios. Conclusion . In this study, a machine learning-based model for preoperative 90-day mortality prediction was developed. It demonstrated good validity and high discriminative performance. The findings support the promise of machine learning methods for clinical risk prediction in cancer surgery and highlight their potential for implementation in routine healthcare practice.